The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
Ling-Long TangYu-Pei ChenChuan-Ben ChenMing-Yuan ChenNian-Yong ChenXiao-Zhong ChenXiao-Jing DuWen-Feng FangMei FengJin GaoFei HanXia HeChao-Su HuDe-Sheng HuGuang-Yuan HuHao JiangWei JiangFeng JinJin-Yi LangJin-Gao LiShao-Jun LinXu LiuQiu-Fang LiuLin MaHai-Qiang MaiJi-Yong QinLiang-Fang ShenYuyao SunPei-Guo WangRen-Sheng WangRuo-Zheng WangXiao-Shen WangYing WangHui WuYun-Fei XiaShao-Wen XiaoKun-Yu YangJun-Lin YiXiao-Dong ZhuJun MaPublished in: Cancer communications (London, England) (2021)
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi-disciplinary team comprising of experts from all sub-specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence-based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow-up of NPC, which aim to improve the management of NPC.